Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Alec Machiels, insider at Apellis Pharmaceuticals
Alec Machiels Insider Alerts

Get notified the next time Alec Machiels buys or sells Apellis Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Alec Machiels Insider Information

Alec Machiels is the Founder and Managing Partner of CoLift, a new private equity platform bringing together a global network of leaders with bespoke investment opportunities. He was a Partner at Pegasus Capital Advisors, L.P., a private equity fund manager with approximately $2bn in assets under management. Mr. Machiels was a member of the firm’s executive and investment committees. He has over 20 years of private equity investing and investment banking experience. Previously, Mr. Machiels was a financial analyst in the Financial Services Group at Goldman Sachs International in London and in the Private Equity Group at Goldman Sachs & Co. in New York. Investments in which he has been highly involved include Pure Biofuel, Molycorp Minerals, Traxys, Slipstream Communications, Coffeyville Resources, and Merisant Company. He also co-founded and serves as a board member of Potentia Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc. which respectively have drugs in Phase III development to treat macular degeneration and rare diseases. He also served as a member of the board of trustees of the American Federation of Arts, where he chaired the endowment committee. Mr. Machiels is a graduate of Harvard Business School, KU Leuven Law School in Belgium, and Konstanz University in Germany.

What is Alec Machiels' net worth?

The estimated net worth of Alec Machiels is at least $28.02 million as of July 15th, 2021. Mr. Machiels owns 672,044 shares of Apellis Pharmaceuticals stock worth more than $28,024,235 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Machiels may own. Learn More.

How do I contact Alec Machiels?

The corporate mailing address for Mr. Machiels and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]

Has Alec Machiels been buying or selling shares of Apellis Pharmaceuticals?

Alec Machiels has not been actively trading shares of Apellis Pharmaceuticals during the past quarter. Most recently, Alec Machiels sold 2,500 shares of the business's stock in a transaction on Thursday, July 15th. The shares were sold at an average price of $62.30, for a transaction totalling $155,750.00. Following the completion of the sale, the director now directly owns 672,044 shares of the company's stock, valued at $41,868,341.20.

Who are Apellis Pharmaceuticals' active insiders?

Apellis Pharmaceuticals' insider roster includes Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Federico Grossi (Insider), Alec Machiels (Director), Nicole Perry (VP), and Lukas Scheibler (Insider).

Are insiders buying or selling shares of Apellis Pharmaceuticals?

During the last twelve months, Apellis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 250,000 shares worth more than $10,000,000.00. During the last twelve months, insiders at the sold shares 33 times. They sold a total of 289,486 shares worth more than $15,318,636.12. The most recent insider tranaction occured on November, 18th when Major Shareholder Morningside Venture Investment bought 250,000 shares worth more than $10,000,000.00. Insiders at Apellis Pharmaceuticals own 9.5 % of the company.

Information on this page was last updated on 11/18/2021.

Alec Machiels Insider Trading History at Apellis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/15/2021Sell2,500$62.30$155,750.00672,044View SEC Filing Icon  
6/15/2021Sell2,500$64.83$162,075.00672,044View SEC Filing Icon  
4/21/2021Sell2,500$45.76$114,400.00672,044View SEC Filing Icon  
3/15/2021Sell2,500$46.77$116,925.00672,044View SEC Filing Icon  
1/15/2021Sell2,500$53.15$132,875.00672,044View SEC Filing Icon  
11/16/2020Sell2,500$39.38$98,450.00672,044View SEC Filing Icon  
10/15/2020Sell2,500$35.00$87,500.00672,044View SEC Filing Icon  
10/7/2020Sell7,500$35.00$262,500.00677,044View SEC Filing Icon  
6/15/2020Sell2,500$30.21$75,525.00
See Full Table

Alec Machiels Buying and Selling Activity at Apellis Pharmaceuticals

This chart shows Alec Machiels's buying and selling at Apellis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $41.70
Low: $41.18
High: $43.93

50 Day Range

MA: $36.85
Low: $30.74
High: $47.11

2 Week Range

Now: $41.70
Low: $27.50
High: $73.00

Volume

1,028,695 shs

Average Volume

1,532,292 shs

Market Capitalization

$3.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!